Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
May 22, 2026Natural Product CommunicationsOpen Access

Natural Compounds Targeting Profibrotic Signaling Pathways in Myocardial Fibrosis: Signaling Network Regulation and Therapeutic Potential

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Myocardial fibrosis is a common pathological process in cardiac diseases that impairs cardiac function and causes sudden death, but effective and safe therapies are currently limited.

Design

Review

Key result

Natural compounds can modulate multiple profibrotic signaling pathways to improve myocardial fibrosis, though comprehensive data on their clinical efficacy and long-term safety are still lacking.

Authors

YLYanxin LiLZLuwen ZhangMLM Li

Discussion

Loading...

Member takes

Overview

May offer adjunctive options for MF with limited therapies; extends preclinical signals but requires confirmatory RCTs.

Key Points

  • This review aims to explore natural compounds that target profibrotic signaling pathways in myocardial fibrosis. It highlights the potential of these compounds in treating myocardial fibrosis effectively.
  • Summarizes advances in natural compounds for myocardial fibrosis treatment.
  • Reviews signaling pathway modulation by various natural compounds.
  • Discusses pharmacokinetics, bioavailability, and clinical implications.
  • Natural compounds like Salvianolic acid B and Curcumin significantly reduce profibrotic cytokines and collagen deposition.
  • These compounds improve myocardial fibrosis and enhance ECM degradation.
  • The review identifies gaps in knowledge about long-term safety and clinical efficacy of these compounds.

Structured PICO

P
Population
Myocardial fibrosis (MF) in various cardiac diseases, including myocardial infarction (MI), hypertensive heart disease, and dilated cardiomyopathy
I
Intervention
Natural compounds (e.g., Salvianolic acid B, Astragaloside IV, Pachymic acid, Resveratrol, Curcumin, Matrine, Artemisinin, and Artesunate)

Natural compounds show therapeutic potential for myocardial fibrosis by regulating profibrotic signaling pathways, though clinical translation requires further pharmacokinetic and clinical trial data.

Limitations

  • Comprehensive data on the pharmacokinetics, bioavailability, long-term safety, and clinical efficacy of these natural compounds are still lacking.
  • Lack of comprehensive data on pharmacokinetics, bioavailability, long-term safety, and clinical efficacy

Cite This Study

Li et al. (2026) conducted a review in Myocardial fibrosis. Natural compounds was evaluated. Natural compounds can modulate multiple profibrotic signaling pathways to improve myocardial fibrosis, though comprehensive data on their clinical efficacy and long-term safety are still lacking.

synapsesocial.com/papers/6a0ff3ecd674f7c03778ce68https://doi.org/10.1177/1934578x261454083
View Full Paper
Ask AI
Bookmark
Share